Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Lutathera (lutetium Lu 177 dotatate)
i
Other names:
177Lu-DOTATATE, [Lu-177]-Dota-Tyr3-Octreotate, [Lu-177]-DOTATATE, octreotate Lu-177 DOTA Tyr-3, 177Lu-[DOTA0, Tyr3] octreotate, 177Lu-DOTA0-Tyr3-octreotate, Lu-DOTATATE, 177Lu-DOTA-Octreotate, 177Lu-DOTA-tyr3-Octreotate, AAA601, AAA 601, AAA-601, [177Lu]Lu-DOTA-TATE
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Novartis
Drug class:
Beta radiation emitter, SSTR2 modulator
Related drugs:
‹
177Lu-lilotomab satetraxetan (4)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
CLR 131 (2)
AAA614 (2)
PNT2002 (2)
177Lu-DOTA-EB-FAPI (0)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-HER3 ARC (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
90Y-PPMX-T002 (0)
TLX66 (0)
AAA603 (0)
iobenguane I 131 (0)
iodine I 131 tositumomab (0)
CAM-H2 (0)
Cu-67 SAR-Bombesin (0)
EBTATE (0)
ITM-91 (0)
Iodine-131-labeled metuximab (0)
ITM-31 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
131I-omburtamab (0)
yttrium-90 microspheres (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
yttrium 90 microspheres (0)
Re (0)
177 Lu-FC705 (0)
Iomab-ACT (0)
OTSA101-DTPA-90Y (0)
RYZ101 (2)
ORM-2110 (1)
VMT-𝛼-NET (0)
177Lu-lilotomab satetraxetan (4)
lutetium Lu 177 vipivotide tetraxetan (4)
ibritumomab tiuxetan (3)
CLR 131 (2)
AAA614 (2)
PNT2002 (2)
177Lu-DOTA-EB-FAPI (0)
TLX250 (0)
177Lu-DTPA-omburtamab (0)
177Lu-HER3 ARC (0)
177Lu-LNC1003 (0)
177Lu-LNC1004 (0)
177Lu-LNC1010 (0)
177Lu-P17-087 (0)
177Lu-P17-088 (0)
177Lu-PSMA-R2 (0)
CYT 500 (0)
TLX591 (0)
90Y-NM600 (0)
90Y-PPMX-T002 (0)
TLX66 (0)
AAA603 (0)
iobenguane I 131 (0)
iodine I 131 tositumomab (0)
CAM-H2 (0)
Cu-67 SAR-Bombesin (0)
EBTATE (0)
ITM-91 (0)
Iodine-131-labeled metuximab (0)
ITM-31 (0)
epratuzumab Y-90 (0)
MVT-1075 (0)
131I-omburtamab (0)
yttrium-90 microspheres (0)
lutetium-177 DOTA satoreotide (0)
67Cu MeCOSar octreotate (0)
177Lu-edotreotide (0)
yttrium 90 microspheres (0)
Re (0)
177 Lu-FC705 (0)
Iomab-ACT (0)
OTSA101-DTPA-90Y (0)
RYZ101 (2)
ORM-2110 (1)
VMT-𝛼-NET (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
SSTR positive
Neuroendocrine Tumor
SSTR positive
Neuroendocrine Tumor
lutetium Lu 177 dotatate
Sensitive: A1 - Approval
lutetium Lu 177 dotatate
Sensitive
:
A1
lutetium Lu 177 dotatate
Sensitive: A1 - Approval
lutetium Lu 177 dotatate
Sensitive
:
A1
SSTR2 underexpression
Neuroendocrine Tumor
SSTR2 underexpression
Neuroendocrine Tumor
lutetium Lu 177 dotatate
Sensitive: D – Preclinical
lutetium Lu 177 dotatate
Sensitive
:
D
lutetium Lu 177 dotatate
Sensitive: D – Preclinical
lutetium Lu 177 dotatate
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.